Dual antiplatelet pre-treatment with aspirin and ticagrelor in ACS patients undergoing unplanned aortocoronary bypass surgery
Clinical Research in Cardiology · 2025
DOI: 10.1007/s00392-025-02629-0 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Clinical Research in Cardiology, 2025. Verfasst von Christian Salbach und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine III, Cardiology, University Hospital of Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany. Hauptthemen laut MEDLINE: Ticagrelor, Coronary Artery Bypass, Aspirin, Acute Coronary Syndrome. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Heidelberg.
Abstract (Originalsprache)
Background
Major bleedings following coronary artery bypass grafting (CABG) have significant implications on outcomes in acute coronary syndrome (ACS) patients. Owing fears of fatal bleedings in case of urgent CABG, current guidelines recommend a cessation of P2Y 12 receptor antagonists (P2Y 12 -RA) before cardiac surgery and opt against routine pre-treatment with a P2Y 12 -RA before coronary angiography (CA). However, sparse information exists outside randomized trials on the frequency of urgent CABG and the consequences of inappropriately long cessation of P2Y 12 -RA treatment in patients presenting with ACS.
Methods
In this observational single-center study, ACS patients presenting to an emergency department requiring a CABG were recruited consecutively during a 2-year enrolment period. Baseline characteristics, CABG-related bleedings and all-cause mortality were collected from electronical medical records and related to the timing of CABG and P2Y 12 -RA cessation.
Results
A total of 1,502 ACS patients were included, herein 102 (6.8%) underwent urgent CABG. The majority (76.5%) received a routine P2Y 12 -RA pre-treatment predominantly ticagrelor in addition to low-dose aspirin before CA. 31 (30.4%) developed a CABG-related bleeding event. Bleeding probability was highest (HR: 4.77, 95%CI 2.20–10.37, p = 0.0001) when CABG was performed within 24 h after administration of dual anti-platelet therapy (DAPT). Despite high utilization rates of DAPT pre-treatment and high prevalence of CABG-related major bleedings, no fatal bleedings occurred.
Conclusions
Need of urgent CABG in ACS is infrequent and does not result in an excess of mortality. However, cessation of ticagrelor for at least 48 h before CABG is recommended to minimize rates of CABG-related bleedings. Graphical Abstract
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine III, Cardiology, University Hospital of Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.
- Department of Internal Medicine III, Cardiology, University Hospital of Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany. evangelos.giannitsis@med.uni-heidelberg.de.
Förderung
- Universitätsklinikum Heidelberg
Zitieren
APA
Salbach, C., Yildirim, M., Gulba, R., Milles, B. R., Biener, M., Mueller-Hennessen, M., Hund, H., Frey, N., & Giannitsis, E. (2025). Dual antiplatelet pre-treatment with aspirin and ticagrelor in ACS patients undergoing unplanned aortocoronary bypass surgery. Clinical Research in Cardiology. https://doi.org/10.1007/s00392-025-02629-0
Vancouver
Salbach C, Yildirim M, Gulba R, Milles BR, Biener M, Mueller-Hennessen M, et al. Dual antiplatelet pre-treatment with aspirin and ticagrelor in ACS patients undergoing unplanned aortocoronary bypass surgery. Clinical Research in Cardiology. 2025. doi:10.1007/s00392-025-02629-0
BibTeX
@article{Salbach2025,
author = {Salbach, Christian and Yildirim, Mustafa and Gulba, Rebecca and Milles, Barbara Ruth and Biener, Moritz and Mueller-Hennessen, Matthias and Hund, Hauke and Frey, Norbert and Giannitsis, Evangelos},
title = {Dual antiplatelet pre-treatment with aspirin and ticagrelor in ACS patients undergoing unplanned aortocoronary bypass surgery},
journal = {Clinical Research in Cardiology},
year = {2025},
doi = {10.1007/s00392-025-02629-0}
}
EUVIMED